Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | TK1 | P04183 | 5/20 | 0.40 |
| ▸ | TYMP | P19971 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24205178 | 0.83 | MAPK1 (0.45) | MAPK1HPGDTK1TYMPALDH1A1 | |
| SCHEMBL1058809 | 0.81 | MAPK1 (0.59) | MAPK1HPGDTK1TYMPALDH1A1 | |
| SCHEMBL28799576 | 0.79 | MAPK1 (0.41) | MAPK1HPGDTK1TYMP | |
| SCHEMBL355903 | 0.77 | MPO (0.38) | MAPK1ALDH1A1 | |
| SCHEMBL456976 | 0.77 | KDM4E (0.44) | MAPK1HPGDTK1TYMPALDH1A1 | |
| SCHEMBL10105028 | 0.72 | KMT2A (0.40) | MAPK1HPGDTK1TYMPALDH1A1 | |
| SCHEMBL20743084 | 0.71 | TK2 (0.55) | MAPK1HPGDTK1TYMP | |
| SCHEMBL4261833 | 0.71 | GRIN2D (0.36) | ALDH1A1 | |
| SCHEMBL28021080 | 0.71 | TK1 (0.36) | MAPK1HPGDTK1TYMPALDH1A1 | |
| SCHEMBL28216800 | 0.71 | MAPK1 (0.40) | MAPK1HPGDTK1TYMPALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322842-A1 | COMPOSITION CONTAINING NUCLEIC ACID OLIGOMER | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2023-10-12 | — | — | US | disclosed |
| US-11530408-B2 | Therapeutic compositions | ALNYLAM PHARMACEUTICALS, INC. (US) | 2022-12-20 | — | — | US | disclosed |
| US-11312957-B2 | Modified iRNA agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2022-04-26 | — | — | US | disclosed |
| US-10806791-B2 | Carbohydrate conjugates as delivery agents for oligonucleotides | ALNYLAM PHARMACEUTICALS, INC. (US) | 2020-10-20 | — | — | US | disclosed |
| US-20200255833-A1 | THERAPEUTIC COMPOSITIONS | BANK OF AMERICA, N.A. | 2020-08-13 | — | — | US | disclosed |
| US-20200061097-A1 | RIG-I AGONISTS AND METHODS USING SAME | HOWARD HUGHES MEDICAL INSTITUTE | 2020-02-27 | — | — | US | disclosed |
| US-10550386-B2 | Monomers and oligonucleotides comprising cycloaddition adduct(s) | ALNYLAM PHARMACEUTICALS, INC. (US) | 2020-02-04 | — | — | US | disclosed |
| US-20190345498-A1 | MODIFIED iRNA AGENTS | BANK OF AMERICA, N.A. | 2019-11-14 | — | — | US | disclosed |
| US-20190184018-A1 | CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES | BANK OF AMERICA, N.A. | 2019-06-20 | — | — | US | disclosed |
| US-20170107513-A1 | MONOMERS AND OLIGONUCLEOTIDES COMPRISING CYCLOADDITION ADDUCT(S) | BANK OF AMERICA, N.A. | 2017-04-20 | — | — | US | disclosed |
| US-20160264968-A1 | MODIFIED iRNA AGENTS | ALNYLAM PHARMACEUTICALS, INC. | 2016-09-15 | — | — | US | disclosed |
| CN-103841827-A | Small molecule compounds for controlling plant-and insect-pathogenic nematodes | CALIFORNIA INST OF TECHN | 2014-06-04 | — | — | CN | disclosed |
| US-20050186591-A1 | Method of treating neurodegenerative disease | ALNYLAM PHARMACEUTICALS | 2005-08-25 | — | — | US | disclosed |
| US-20050153337-A1 | iRNA conjugates | ALNYLAM PHARMACEUTICALS, INC. | 2005-07-14 | — | — | US | disclosed |
| CN-1308684-A | Method for identifying drug action route | ROSETTA INPHARMATICS INC (US) | 2001-08-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050153337-A1 | iRNA conjugates | AGO2, NSUN3, RNASE1 | MAPK1 4799/4885HPGD 4731/4885TK1 2803/4885 |
| US-20190184018-A1 | CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES | SLC2A2, SLC2A8, SLC2A1 | MAPK1 4247/4885HPGD 4624/4885TK1 282/4885 |
| US-20190345498-A1 | MODIFIED iRNA AGENTS | NCL, HNRNPA0, HNRNPA1 | MAPK1 4802/4885HPGD 3555/4885TK1 1232/4885 |
| US-20050186591-A1 | Method of treating neurodegenerative disease | SNCA, PARK7, NLN | MAPK1 4231/4885HPGD 3710/4885TK1 3102/4885 |
| US-20200255833-A1 | THERAPEUTIC COMPOSITIONS | SNRPE, HNRNPH3, RNASE1 | MAPK1 4325/4885HPGD 4184/4885TK1 536/4885 |
| US-20230322842-A1 | COMPOSITION CONTAINING NUCLEIC ACID OLIGOMER | NSUN2, RNGTT, NSUN3 | MAPK1 1867/4885HPGD 4677/4885TK1 307/4885 |
| US-10550386-B2 | Monomers and oligonucleotides comprising cycloaddition adduct(s) | FANCI, PCNA, DNMT1 | MAPK1 2582/4885HPGD 3797/4885TK1 245/4885 |
| US-20170107513-A1 | MONOMERS AND OLIGONUCLEOTIDES COMPRISING CYCLOADDITION ADDUCT(S) | FANCI, PCNA, DNMT1 | MAPK1 2582/4885HPGD 3797/4885TK1 245/4885 |
| US-11530408-B2 | Therapeutic compositions | SNRPE, HNRNPH3, RNASE1 | MAPK1 4325/4885HPGD 4184/4885TK1 536/4885 |
| US-10806791-B2 | Carbohydrate conjugates as delivery agents for oligonucleotides | SLC2A2, SLC2A8, SLC2A1 | MAPK1 4247/4885HPGD 4624/4885TK1 282/4885 |
| US-11312957-B2 | Modified iRNA agents | NCL, HNRNPA0, HNRNPA1 | MAPK1 4802/4885HPGD 3555/4885TK1 1232/4885 |
| US-20200061097-A1 | RIG-I AGONISTS AND METHODS USING SAME | CD274, HAVCR2, MAVS | MAPK1 3614/4885HPGD 4295/4885TK1 2115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.